BBOT — BridgeBio Oncology Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1869105 ·
Last close
$9.14
Market Cap
$732.79M
52W High
$9.78
52W Low
$7.00
ADV30
283,367
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -46,179,000 | -42,106,000 | 417,646,000 | 52,658,000 | 45,366,000 |
| Dec 2025 | 0 | — | -43,408,000 | -38,797,000 | 448,381,000 | 373,687,000 | 37,285,000 |
| Sep 2025 | 0 | — | -49,181,000 | -44,757,000 | 484,793,000 | 408,741,000 | 38,093,000 |
| Jun 2025 | 0 | — | -30,093,000 | -28,435,000 | 151,253,000 | 31,518,000 | 378,986,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-130,212,000
Investing CF
$-227,447,000
Financing CF
$384,101,000
CapEx
$-468,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-527.99
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-398,673,000
Inventory
—
Receivables
$146,000
ST Investments
$199,617,000
EBIT TTM
$-168,861,000
Pretax Income TTM
$-154,095,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -145,819,000 | -134,044,000 | 448,381,000 | 37,285,000 | — | -113,894,000 |
| Dec 2024 | 0 | -80,863,000 | -74,275,000 | 164,301,000 | 342,938,000 | — | -55,027,000 |
| Dec 2023 | 0 | -64,771,000 | -64,699,000 | 5,942,000 | 121,583,000 | — | -52,079,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.41
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OCS | Oculis Holding AG | $731.86M | $13.18 | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $743.94M | $35.31 | — |
| MNPR | Monopar Therapeutics | $747.47M | $111.36 | — |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $718.32M | $35.28 | — |
| CTMX | CytomX Therapeutics, Inc. | $716.89M | $3.29 | — |
News headlines (Yahoo Finance, 1h cache)
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-08-11 20:40 · Yahoo
Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More
2026-05-11 11:58 · Yahoo
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
2026-04-22 20:05 · Yahoo
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
2026-04-21 21:30 · Yahoo
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
2026-08-11 20:05 · Yahoo
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
2026-04-20 20:06 · Yahoo
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential?
2026-06-30 13:06 · Yahoo
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
2026-05-17 18:33 · Yahoo
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
2026-05-17 18:18 · Yahoo
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
2026-05-15 22:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.